Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy - New Zealand
doi 10.2147/btt.s3410
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Efficacy and Adverse Events of Transcatheter Arterial Chemoembolization in Combination With Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Sorafenib Continuation or Discontinuation in Patients With Unresectable Hepatocellular Carcinoma After a Complete Response

Oncotarget
Oncology
2015English

Lenvatinib and Its Use in the Treatment of Unresectable Hepatocellular Carcinoma

Future Oncology
MedicineCancer ResearchOncology
2018English

Retrospective Analysis of Transarterial Chemoembolization and Sorafenib in Chinese Patients With Unresectable and Recurrent Hepatocellular Carcinoma

Oncotarget
Oncology
2016English

Triclosan Treatment Decreased the Antitumor Effect of Sorafenib on Hepatocellular Carcinoma Cells

OncoTargets and Therapy
OncologyPharmacology
2018English

Network Meta-Analysis of Treatments for Unresectable Hepatocellular Carcinoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Successful Treatment of Hepatocellular Carcinoma With Regorafenib After Sorafenib-Induced Hypersensitivity

Internal Medicine
Internal MedicineMedicine
2019English

Pcn188 - Assessing the Robustness of a Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib in Unresectable Hepatocellular Carcinoma in Japan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy